Epidural Study of Patients With Chronic Lower Back Pain
Primary Purpose
Chronic Low Back Pain
Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Bupivacaine
Bupivacaine
Bupivacaine
Bupivacaine
Depo-Medrol
Sponsored by
About this trial
This is an interventional treatment trial for Chronic Low Back Pain focused on measuring epidural, volume, dose, pain relief, steroid
Eligibility Criteria
Inclusion Criteria:
- 18-75 years old
- lower back pains > 6 months
- no lumbar epidural in past 6 months
- no previous back surgery
- written informed consent to participate in study
Exclusion Criteria:
- acute lower back pain
- pregnancy
- significant psychiatric disease
- local or systemic infection
- coagulopathy/anticoagulant therapy
- bleeding diathesis
- presently enrolled in another study
Sites / Locations
- Hamilton General Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Experimental
Arm Label
LV/LD 1
LV/HD 2
HV/LD 3
HV/HD 4
Arm Description
Low Volume, Low Dose (5cc, 5mg plain Bupivacaine) + 80mg Depo-Medrol
Low Volume, High Dose (5cc, 10mg plain Bupivacaine) + 80mg Depo-Medrol
High Volume, Low Dose (10cc, 5mg plain Bupivacaine) + 80mg Depo-Medrol
High Volume, High Dose (10cc, 10mg plain Bupivacaine) + 80mg Depo-Medrol
Outcomes
Primary Outcome Measures
The volume and dose of local anesthetic injected epidurally, in combination with the steroid, will be measured against the duration and degree of pain relief.
Secondary Outcome Measures
Secondary outcomes will be scores on the Oswestry low back pain disability scale and the Hospital anxiety and depression scale correlated with treatment outcomes and adverse events.
Full Information
NCT ID
NCT00887003
First Posted
April 22, 2009
Last Updated
February 7, 2012
Sponsor
Hamilton Health Sciences Corporation
1. Study Identification
Unique Protocol Identification Number
NCT00887003
Brief Title
Epidural Study of Patients With Chronic Lower Back Pain
Official Title
Effects of Volume and Dose of Local Anaesthetic Solution in Epidural Steroidal Injections for Patients With Chronic Lower Back Pain
Study Type
Interventional
2. Study Status
Record Verification Date
July 2011
Overall Recruitment Status
Completed
Study Start Date
May 2005 (undefined)
Primary Completion Date
August 2011 (Actual)
Study Completion Date
September 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hamilton Health Sciences Corporation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to examine 4 different epidural dosing regimes of local anaesthetic solution in a series of 3 epidural injections over a period of 12 months to determine the optimum dose of anaesthetic solution for pain relief and to determine the nature of any adverse events by measuring anxiety and depression, functionality and any side effects of the medication.
Detailed Description
To determine the optimum dose of local anesthetic and the optimum volume of injected solution when used in an epidural steroid injection being given for pain relief to patients with chronic lower back pain, using pain scores as an assessment tool.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Low Back Pain
Keywords
epidural, volume, dose, pain relief, steroid
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
252 (Actual)
8. Arms, Groups, and Interventions
Arm Title
LV/LD 1
Arm Type
Experimental
Arm Description
Low Volume, Low Dose (5cc, 5mg plain Bupivacaine) + 80mg Depo-Medrol
Arm Title
LV/HD 2
Arm Type
Experimental
Arm Description
Low Volume, High Dose (5cc, 10mg plain Bupivacaine) + 80mg Depo-Medrol
Arm Title
HV/LD 3
Arm Type
Experimental
Arm Description
High Volume, Low Dose (10cc, 5mg plain Bupivacaine) + 80mg Depo-Medrol
Arm Title
HV/HD 4
Arm Type
Experimental
Arm Description
High Volume, High Dose (10cc, 10mg plain Bupivacaine) + 80mg Depo-Medrol
Intervention Type
Drug
Intervention Name(s)
Bupivacaine
Other Intervention Name(s)
steroid
Intervention Description
Low Volume, Low Dose (5cc, 5mg plain Bupivacaine)
Intervention Type
Drug
Intervention Name(s)
Bupivacaine
Other Intervention Name(s)
steroid
Intervention Description
Low Volume, High Dose (5cc, 10mg plain Bupivacaine)
Intervention Type
Drug
Intervention Name(s)
Bupivacaine
Other Intervention Name(s)
steroid
Intervention Description
High Volume, Low Dose (10cc, 5mg plain Bupivacaine)
Intervention Type
Drug
Intervention Name(s)
Bupivacaine
Other Intervention Name(s)
steroid
Intervention Description
High Volume, High Dose (10cc, 10mg plain Bupivacaine)
Intervention Type
Drug
Intervention Name(s)
Depo-Medrol
Other Intervention Name(s)
methylprednisolone
Intervention Description
80mg Depo-Medrol
Primary Outcome Measure Information:
Title
The volume and dose of local anesthetic injected epidurally, in combination with the steroid, will be measured against the duration and degree of pain relief.
Time Frame
Pain scores will be measured at 6 time intervals throughout the study period, prior to 1st injection, 30 minutes post 1st injection, prior to 2nd injection and 3rd injections and at 3 and 6 month post the three month injection.
Secondary Outcome Measure Information:
Title
Secondary outcomes will be scores on the Oswestry low back pain disability scale and the Hospital anxiety and depression scale correlated with treatment outcomes and adverse events.
Time Frame
Oswestry scores and HADS scores will be calculated at 5 time periods throughout the study period, prior to 1st, 2nd, and 3rd injections and at 3 and 6 month post the three month injection.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18-75 years old
lower back pains > 6 months
no lumbar epidural in past 6 months
no previous back surgery
written informed consent to participate in study
Exclusion Criteria:
acute lower back pain
pregnancy
significant psychiatric disease
local or systemic infection
coagulopathy/anticoagulant therapy
bleeding diathesis
presently enrolled in another study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Julian Mulcaster, MD
Organizational Affiliation
Hamilton Health Sciences Corporation
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hamilton General Hospital
City
Hamilton
State/Province
Ontario
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
Epidural Study of Patients With Chronic Lower Back Pain
We'll reach out to this number within 24 hrs